Back to today’s briefing

Story perspectives

Novo Nordisk Partners for $2.2B Obesity Drug Revolution

5/15/2025

37 7

Summary

Story summary

Novo Nordisk has struck a groundbreaking $2.2 billion partnership with Septerna to revolutionize oral treatments for obesity and type 2 diabetes. With an initial payment exceeding $200 million, this collaboration seeks to develop innovative small-molecule drugs that target crucial receptors, strengthening Novo's position in a fiercely competitive market.

1 of 1

Story summary

Novo Nordisk has struck a groundbreaking $2.2 billion partnership with Septerna to revolutionize oral treatments for obesity and type 2 diabetes. With an initial payment exceeding $200 million, this collaboration seeks to develop innovative small-molecule drugs that target crucial receptors, strengthening Novo's position in a fiercely competitive market.